Ketoacidosis as unexpected adverse reaction SGLT₂ inhibitor

• Main Authors: T. M. Bukatina (Author), A. S. Kazakov (Author), N. Yu. Velts (Author), M. A. Darmostukova (Author), K. E. Zatolochina (Author), R. N. Alyautdin (Author), V. P. Dobrynin (Author), B. K. Romanov (Author)
• Format: Book
• Published: Ministry of Health of the Russian Federation, Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products», 2018-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Inhibitors of the sodium-glucose cotransporter-2 SGLT2 is a new class of hypoglycemic drugs. This article presents the information on FDA reports (2013-2015) and AIS (May 2015 - February 2016) on the risk of new adverse reaction - ketoacidosis. Conjectural pathophysiological mechanisms of ADR associ...